Payment overview · 2025
General Payments
$294.43
13 reported records · 8 companies
Healthcare provider profile · identity verified
Ehab Michael, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW PORT RICHEY, FL · NPI 1588654222
Verified facts
What the public records show
CMS Open Payments records show Ehab Michael, M.D. received $294.43 in general payments during 2025 across 13 reported records.
GlaxoSmithKline, LLC. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ocaliva, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Trelegy Ellipta by this doctor in 2024.
Intercept Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OCALIVA as an associated drug or biological on 9842 records involving 5240 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ocaliva by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $127.06 | 43.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.39 | 12.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.60 | 10.1% | 2 | 2025 |
| Intercept Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.76 | 9.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.96 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.92 | 7.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.96 | 5.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.78 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.43 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $127.06 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.39 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.60 | 2 | 2025 |
Source payment records
|
|||||
| OCALIVA Normalized: ocaliva |
Drug | Intercept Pharmaceuticals, Inc. | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 45 | exact normalized | Medicare Part D |
| OCALIVA ocaliva |
2025 | Ocaliva | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 175 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
175 | 34 |
| Intercept Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OCALIVA open payments reported associated product |
CMS Open Payments — General Payments 9842 supporting records · 5240 recipient NPIs · example record 1249867901 |
Ocaliva · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 810 | 233 |
| Atorvastatin Calcium | Atorvastatin Calcium | 792 | 203 |
| Lisinopril | Lisinopril | 741 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 161 |
| Metoprolol Succinate | Metoprolol Succinate | 599 | 163 |
| Losartan Potassium | Losartan Potassium | 589 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 551 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 524 | 147 |
| Gabapentin | Gabapentin | 410 | 123 |
| Metformin Hcl | Metformin Hcl | 406 | 115 |
| Metoprolol Tartrate | Metoprolol Tartrate | 323 | 91 |
| Omeprazole | Omeprazole | 309 | 82 |
| Alprazolam | Alprazolam | 306 | 60 |
| Meloxicam | Meloxicam | 294 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 271 | 84 |
| Sertraline Hcl | Sertraline Hcl | 270 | 63 |
| Trazodone Hcl | Trazodone Hcl | 267 | 60 |
| Clonazepam | Clonazepam | 261 | 48 |
| Furosemide | Furosemide | 241 | 71 |
| Glimepiride | Glimepiride | 237 | 67 |
| Simvastatin | Simvastatin | 218 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 214 | 48 |
| Methylprednisolone | Methylprednisolone | 213 | 154 |
| Fluoxetine Hcl | Fluoxetine Hcl | 211 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 68 |
| Nifedipine Er | Nifedipine | 206 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 66 |
| Eliquis | Apixaban | 201 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 53 |
| Cefdinir | Cefdinir | 176 | 137 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 175 | 34 |
| Atenolol | Atenolol | 169 | 41 |
| Tramadol Hcl | Tramadol Hcl | 154 | 33 |
| Montelukast Sodium | Montelukast Sodium | 150 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 41 |
| Buspirone Hcl | Buspirone Hcl | 131 | 32 |
| Lovastatin | Lovastatin | 128 | 30 |
| Carvedilol | Carvedilol | 124 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 121 | 88 |
| Januvia | Sitagliptin Phosphate | 118 | 15 |
| Nystatin | Nystatin | 116 | 47 |
| Potassium Chloride | Potassium Chloride | 116 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 28 |
| Ezetimibe | Ezetimibe | 111 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 111 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 110 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 104 | 82 |
| Memantine Hcl | Memantine Hcl | 104 | 25 |
| Donepezil Hcl | Donepezil Hcl | 96 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 95 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 95 | suppressed |
| Mounjaro | Tirzepatide | 90 | 14 |
| Famotidine | Famotidine | 88 | 33 |
| Allopurinol | Allopurinol | 86 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 84 | 22 |
| Ozempic | Semaglutide | 84 | 16 |
| Ammonium Lactate | Ammonium Lactate | 82 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Spironolactone | Spironolactone | 80 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 80 | 14 |
| Lorazepam | Lorazepam | 79 | 16 |
| Prednisone | Prednisone | 79 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 18 |
| Celecoxib | Celecoxib | 75 | 22 |
| Mirtazapine | Mirtazapine | 75 | 22 |
| Lansoprazole | Lansoprazole | 73 | 22 |
| Azithromycin | Azithromycin | 70 | 61 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 69 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 68 | 59 |
| Bumetanide | Bumetanide | 67 | 16 |
| Ibuprofen | Ibuprofen | 67 | 19 |
| Xarelto | Rivaroxaban | 64 | 18 |
| Meclizine Hcl | Meclizine Hcl | 63 | 29 |
| Valsartan | Valsartan | 62 | 16 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 59 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 58 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 15 |
| Clonidine Hcl | Clonidine Hcl | 55 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 16 |
| Pregabalin | Pregabalin | 54 | 16 |
| Warfarin Sodium | Warfarin Sodium | 53 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 52 | 11 |
| Temazepam | Temazepam | 52 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 11 |
| Bupropion Xl | Bupropion Hcl | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 16 |
| Gemfibrozil | Gemfibrozil | 48 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 12 |
| Jardiance | Empagliflozin | 45 | 15 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Glipizide | Glipizide | 39 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | suppressed |
| Gemtesa | Vibegron | 37 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 20 |
| Lidocaine | Lidocaine | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Sotalol | Sotalol Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | 14 |
| Primidone | Primidone | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 17 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Acyclovir | Acyclovir | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Ocaliva | Obeticholic Acid | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.43 · 13 records | GlaxoSmithKline, LLC. | ACCRUFER, FARXIGA, JARDIANCE, Kerendia, OCALIVA, Ozempic, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error